Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study

DiscussionThe results of this study could influence the therapy of patients with COVID-19 and affect the course of the disease worldwide, as infliximab is globally available and approved by several international drug agencies.Trial registrationThe trial was registered (NCT04922827, 11 June 2021) and at EudraCT (2021-002098-25, 19 May 2021).
Source: Trials - Category: Research Source Type: clinical trials